Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, enzalutamide, first line, outcome, PSA | 2 Comments »
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, galeterone, TOK-001, trial | Leave a Comment »
The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, deprivation, response, sub-optimal | Leave a Comment »
There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone acetate, enzalutamide and others for the treatment of advanced and progressive forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, combination, enzalutamide, radium-223, sequencing, sipuleucel-T | 14 Comments »
An editorial by Freeman and Solomon (“Statin drugs and prostate cancer: time to consider proactive strategies in patients“) in the April issue of the Journal of Urology has proposed the idea of combining abiraterone acetate with a statin as a method to treat men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, catration-resistant, CRPC, statin | Leave a Comment »
The UroToday web site has just posted a detailed report on a presentation by Stephen Freedland, MD, of Duke University, given at the South East Section meeting of the American Urological Association in Williamsburg, VA, last month. This report will likely be of interest to patients with progressive forms of prostate cancer and many support group leaders. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, Management | 5 Comments »
An article with the above headline appears on the Science web site this week. It refers to the apparent biological effects of an antibody known as anti-CD47 and work on the development of this agent by Irving Weissman and colleagues at Stanford University School of Medicine. … READ MORE …
Filed under: Drugs in development | Tagged: anti-CD47 | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site